Spear Bio reported that SPEAR TrueDetect™ epTau 217 delivered highly consistent measurements across venous blood and Tasso capillary blood samples in paired-sample testing.
Public source
Publisher name
Public post
🩸 Could capillary blood collection broaden how Alzheimer’s disease biomarker studies are designed? In paired-sample testing, SPEAR TrueDetect™ epTau 217 delivered highl…
Company
Spear Bio
The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity.
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 51–200 employees
About Spear Bio
Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio.
See moreLatest activity
Latest activity from Spear Bio
6 signals
Presence & Recognition
Spear Bio and Banner Health will present new data on SPEAR epTau 217 and SPEAR eMTBR-Tau at a 60-minute virtual webinar on Wednesday, September 9.
Partnerships
Spear Bio announced that Microcoat Biotechnologie GmbH is bringing SPEAR technology in-house to expand sponsor access to ultra-sensitive, low-volume biomarker testing within its regulated CRO environment.
Products & Services
Spear Bio announced that its assays will soon be available as a service through Microcoat Biotechnologie GmbH.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Diasorin
Diasorin reported that plasma p-tau217 moved primary care physicians from roughly 65% to 93% accuracy in suspected Alzheimer’s off a routine blood draw.
Research & Knowledge
Quanterix
Quanterix brand Lucent Diagnostics released LucentAD Complete, a multi-analyte biomarker test from Lucent Diagnostics that detects p-Tau 217, Amyloid Beta (AB42/40 Ratio), Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP) in the blood to improve amyloid status classification and reduce the diagnostic gray zone by two-thirds.
Research & Knowledge
Harvard Bioscience
Harvard Bioscience published a recent study investigating how a brain-penetrating, bispecific amyloid-beta antibody distributes within the brain and interacts with aggregated Aβ in an Alzheimer’s disease mouse model using CMA Microdialysis technology.
Research & Knowledge
Alamar Biosciences, Inc.
Alamar Biosciences, Inc. published a Biomarker Edge blog by CSO Stephen Williams, MD, PhD, exploring why amyloid alone doesn’t tell the whole Alzheimer’s story and how direct measurement of eMTBR-Tau could help address a critical gap in blood-based Alzheimer’s research.
Research & Knowledge
Neurotrack